A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors-论文-万方医学网

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

导出原文传递

翻译打印收藏纠错

作者： Zhu, Mojun ^[1] ; Molina, Julian R. ^[2] ; Dy, Grace K. ^[3] ; Croghan, Gary A. ; Qi, Yingwei ; Glockner, James ; Hanson, Lorelei J. ; Roos, Michelle M. ; Tan, Angelina D. ; Adjei, Alex A.

作者单位： Mayo Clin, 200 First St SW, Rochester, MN 55905 USA ^[1] Roswell Park Canc Inst, Buffalo, NY 14263 USA ^[2] Dign Hlth Med Fdn, San Francisco, CA 94107 USA ^[3]

关键词 Phase I Targeted therapy Vatalanib Everolimus

发布时间 2022-09-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

相似文献

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

相似文献

相关期刊

检索历史清除